Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Pre-Solicitation opportunity was posted on July 27, 2012. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Anti-Muellerian-Hormone levels and ovarian cancer risk in the JANUS biobank

Awarded
NCI-120133-TGFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325413
New
Federal
6550--Blood Type IVD Reagents
Solicitation # 36C26227Q0043
The Department of Veterans Affairs, through the Network Contract Office 22, is seeking quotations for solicitation 36C26227Q0043 to establish a Blanket Purchase Agreement for blood type IVD reagents, supplies, and consumables for manual testing at VISN 22 facilities. The contract is structured with a 12-month base ordering period and four subsequent 12-month option periods, for a total potential duration of five years. This is a commercial products and services acquisition under FAR Part 12, with an emphasis on FDA regulatory compliance, potency requirements, and strict cold-chain and temperature-monitoring controls during shipment. All items must be quoted as F.O.B. destination and delivered Monday through Friday between 8am and 4pm. Award will be based on the best value to the government, evaluated through a comparative assessment of technical understanding, price, and quality, regulatory compliance, and product traceability. Technical evaluation considers the offeror's ability to provide a full antigen profile and their procedures for handling nonconforming or defective products. Pricing will be evaluated based on the total cost for the base period and all option periods, including a six-month price addition for the final performance period per FAR 52.217-8. Quotations must be submitted via email to the contract specialist by November 16, 2026, and must include a completed five-year pricing spreadsheet, a past performance questionnaire, and required certifications regarding telecommunications and trade agreements.
262-NETWORK Contract Office 22 (36C262)

POSTED

about 6 hours ago

DEADLINE

in 17 days
NAICS: 325413
New
DIBBS
CULTURE MEDIUM, THAYER-
Solicitation # SPE2DS-27-T-1066
Solicitation SPE2DS-27-T-1066 is a request for quotations issued by the DLA Troop Support Medical Supply Chain for the procurement of one package of Thayer-Martin Modified (MTM II) Agar culture medium, identified by NSN 6550-01-711-1542. This dark brown, ready-to-use plated medium is specifically designed for the isolation of pathogenic Neisseria from specimens containing mixed flora of bacteria and fungi. The product is delivered in packages of 100 plates and requires strict refrigeration storage between 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) and must not be frozen. The contract mandates a non-extendable shelf life of three months, with a requirement that no more than 14 days elapse between the date of manufacture and the date of delivery to the government. Delivery is set for JBER, Alaska, with a required delivery date of October 27, 2026, under FOB Destination terms. Packaging must be commercial and sealed to prevent damage, with marking adhering to Medical Marking Standard No. 1 and shelf-life labels following MMS1C. Administrative requirements include electronic invoicing via the Wide Area WorkFlow system and compliance with various FAR and DFARS clauses, including the Buy American Act, Berry Amendment, and safeguarding of covered defense information. Evaluation will consider technical data for any alternate products offered and may include HUBZone price evaluation preferences. Inspection and acceptance will occur at the destination.
MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

2 days ago

DEADLINE

in 4 days
NAICS: 325413
New
Federal
6550--Optilite analyzer reagents
Solicitation # 36C26227Q0052
The Department of Veterans Affairs, Southern Arizona Healthcare System, is soliciting a Firm-Fixed Price Blanket Purchase Agreement under solicitation 36C26227Q0052 for the procurement of FDA-approved reference testing reagents and consumables validated for use on the Optilite analyzer. The scope includes specific items such as Freelite Kappa, Freelite Lambda, and Ceruloplasmin reagents, as well as TENCELL cuvettes and sample cups. To ensure system performance and safety, all materials must be manufactured by Binding Site Laboratories, and substitutions are prohibited. The contract is issued as a full and open competition under NAICS code 325413, with a total estimated period of performance of sixty months, consisting of a base period from November 9, 2026, to November 8, 2027, followed by four one-year option periods. The award will be granted to the responsible offeror whose proposal is most advantageous to the government, based on a technical acceptability review of the Statement of Work and the lowest price. Deliveries are required to be made to various VA Medical Centers across Arizona, California, and New Mexico, with standard orders delivered within four working days of placement. All shipments must be destination-based, with the vendor assuming all shipping costs and adhering to strict packaging standards to prevent damage. Invoicing is handled electronically through the Department of Veterans Affairs Financial Services Center in accordance with the Prompt Payment Act. Quotes must be submitted via email to Contract Specialist Carlos Magana by November 4, 2026.
262-NETWORK Contract Office 22 (36C262)

POSTED

3 days ago

DEADLINE

in 5 days
NAICS: 325413
Federal
BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
Solicitation # HT942627QE003
The Defense Health Agency is soliciting quotations to establish a Blanket Purchase Agreement (BPA) for the recurring resupply of consumable products for three Terumo Trima Accel Blood Collection Systems used by the USAISR Combat Casualty Care Research Team 1 in Texas. To maintain FDA approval and satisfy research protocols, the contractor must provide original manufacturer-supplied consumables, including Teruflex 500ml collection bags, Trima Platelet Kits, Isoplate Solution (PAS-F), TSCD Wafers, ACD-A Solution, and 150 mL couplers. This procurement is a 100 percent set-aside for Service-Disabled Veteran-Owned Small Businesses under NAICS 325413. The resulting BPA will have a 60-month ordering period with a total ceiling of 35 million dollars, though some documentation notes a lower limit of 350,000 dollars. Individual call orders are capped at 50,000 dollars, while Government Purchase Card orders are limited to 15,000 dollars. Awards will be made on a Lowest Price Technically Acceptable basis, with technical capability rated as pass or fail. All payment requests and receiving reports must be processed electronically through the Wide Area WorkFlow system. Quotations are due by November 6, 2026, and must be submitted in two separate volumes covering technical capability and pricing.
Army Medical Resources Acq Activity

POSTED

7 days ago

DEADLINE

in 7 days

General Info

Agency

N/A

Contract Value

$56,903

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

Not specified

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded
Posted

Presolicitation

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts2 people available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Terry GallowayContract Specialist
Caren N RasmussenContracting Officer

Full Description

Show more
Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Room 6074, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB), plans to procure on a sole source basis pre-diagnostic serum samples from women with ovarian cancer and controls from the JANUS BioBank from Oslo Universitetssykehus, Fridtjog Nansens vei 19, Mojorstuen, Oslo, Norway. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System code is 325414 and the business size standard is 500 Employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be from award through twelve (12) months. It has been determined there are no opportunities to acquire green products or services for this procurement. The Hormonal and Reproductive Epidemiology Branch (HREB) conducts research to identify groups at high risk of cancer, clarify the natural history of various cancers, understand the interactive effects of genetic and environmental factors on cancer risk, and elucidate biologic mechanisms of carcinogenesis. Ovarian cancer is the most fatal gynecologic malignancy. Several reproductive factors are associated with ovarian cancer risk, including parity, age at menarche, age at menopause and lifetime ovulatory cycles. Anti-Muellerian Hormone (AMH) is a protein hormone from the TGF-beta family that is expressed in granulosa cells of growing non-selected follicles. AMH serves as a marker of ovarian function and is routinely evaluated to evaluate infertility. AMH levels increase with puberty and decrease until menopause when AMH levels become undetectable. The relationship of AMH with reproductive risk factors for ovarian cancer and experimental data indicating that AMH can suppress ovarian cancer growth suggest that increased AMH levels may be associated with decreased risk of ovarian cancer. So far, no study has evaluated the association between circulating AMH levels and ovarian cancer risk, in part related to the requirement to measure AMH levels in pre-menopausal blood draws. NCI plans to conduct a study of AMH levels and ovarian cancer risk nested in the JANUS serum bank. The contractor shall identify serum samples from 200 women with ovarian cancer and 200 women without cancer enrolled in the JANUS biobank and 40 quality control samples and provide aliquots to the NCI. The contractor shall also conduct database linkages to the Institute of Public Health of Norway, to the Medical Birth Registry of Norway and to the Cancer Registry of Norway to identify the following variables: Age, parity, age at birth, oral contraceptive use, smoking, height, weight, BMI, infertility, IVF treatment, age at menarche, mother's health variables, tumor histology, grade, stage. The JANUS biobank is a unique resource that provides serum samples with premenopausal blood draws from a large number of women who were followed through nationwide registries for cancer incidence. Thus, the JANUS biobank is the only resource that allows conducting a well-powered study of circulating AMH levels and ovarian cancer risk from a single site. The above mentioned samples to be used for this project are in the sole possession of the Oslo Universitetssykehus. Thus the Oslo Universitetssykehus is the only known source for this requirement. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 13, 2012. For further information, please contact Terry Galloway, Contract Specialist via electronic mail at contact@example.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-120133-TG on all correspondence.

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS